Dulaglutide
Dulaglutide (GLP-1 Receptor Agonist)
A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes (Trulicity). Has demonstrated cardiovascular risk reduction in the REWIND trial.
Mechanism of Action
Dulaglutide is a GLP-1 analogue fused to an IgG4 Fc fragment, extending its half-life to allow once-weekly dosing. It activates GLP-1 receptors to stimulate insulin, suppress glucagon, and reduce appetite.
Health Claims & Evidence
Improves glycemic control in type 2 diabetes
Reduces cardiovascular risk
Promotes modest weight loss
Short-Term Effects
Improved glycemic control, nausea initially, modest weight loss.
Long-Term Effects
Sustained glycemic control and cardiovascular risk reduction.
Side Effects
Nausea, vomiting, diarrhea. Rare: pancreatitis.
Contraindications
Avoid with personal/family history of medullary thyroid carcinoma.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Dulaglutide and cardiovascular outcomes
Gerstein et al. · Lancet · 2019
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Dulaglutide and related peptides, and prepare an educational research summary.
Explore Research